Acasă › Limfom Burkitt › Hawaii
Studii clinice pentru Limfom Burkitt în Hawaii
5 studii pentru Limfom Burkitt caută participanți în Hawaii.
Orașe în Hawaii
Text oficial al studiului (în engleză)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Kapiolani Medical Center for Women and Children, Honolulu
În curs de recrutareFaza 2
366 Days – 46 Years · Toate sexele · Actualizat 2 oct. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Straub Clinic and Hospital, Honolulu
- Kapiolani Medical Center for Women and Children, Honolulu
- Pali Momi Medical Center, ‘Aiea
În curs de recrutareFaza 3
Vârste de la 18 la 39 · Toate sexele · Actualizat 2 oct. 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Kapiolani Medical Center for Women and Children, Honolulu
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Kapiolani Medical Center for Women and Children, Honolulu
În curs de recrutareFaza 2
Vârste de la 1 la 30 · Toate sexele · Actualizat 1 sept. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Kapiolani Medical Center for Women and Children, Honolulu
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.